ArticleBMC immunology2026
MicroRNA-18a-3p as a biomarker for neonatal respiratory distress syndrome and its effects in alveolar epithelial type II cells.
Article in BMC immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeonatal respiratory distress syndrome (NRDS) is a major cause of significant morbidity and mortality among neonates, particularly in preterm infants. Existing studies have highlighted various microRNAs (miRNAs) implicated in NRDS, yet the precise molecular mechanisms, particularly regarding miR-18a-3p, remain incompletely understood. This research aimed to elucidate the role of miR-18a-3p as a potential biomarker for NRDS and to explore its functional mechanisms in alveolar type II epithelial cells.
methodA total of 35 NRDS patients and 35 healthy controls were enrolled, with samples of amniotic fluid and neonatal blood collected for expression analysis of miR-18a-3p. Utilizing cell culture, transfection, qRT-PCR techniques, CCK-8 assay, and ELISA assay, the function of miR-18a-3p in alveolar epithelial type II cells (an immortalized cell line, IHPEC-II, and AEC2-like cells derived from human pluripotent stem cells) was investigated. The binding relationship between miR-18a-3p and surfactant pulmonary-associated protein C (SFTPC) was predicted and validated using a dual-luciferase reporter assay.
resultsElevated levels of miR-18a-3p levels were observed in the serum of NRDS cases, with an area under the ROC curve (AUC) of 0.86 for distinguishing NRDS from healthy controls. Increased miR-18a-3p levels were also detected in amniotic fluid from these NRDS cases, yielding an ROC AUC of 0.82 for discriminating between NRDS cases and healthy controls. A positive correlation between serum miR-18a-3p levels and those in amniotic fluid was observed. Functional assays demonstrated that inhibition of miR-18a-3p significantly enhanced cell viability and increased SPC secretion in alveolar epithelial type II cells following surfactant stimulation. Dual-luciferase reporter assays confirmed that miR-18a-3p modulated SFTPC expression.
conclusionMiR-18a-3p was increased in NRDS cases. MiR-18a-3p can inhibit alveolar epithelial type II cell function, suggesting its potential role in fetal lung development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.